and costs of a newly-initiated, managed care predialysis chronic kidney
disease population receiving EPO (n=1,066) or DARB (n=375) through a
pharmacy benefit. Drug cost was based on cumulative dose and October
2007 wholesale acquisition cost.
Data on Medical Costs Related to Chronic Kidney Disease Patients with
Hypertension or Diabetes
-- Abstract: Medical Costs of Chronic Kidney Disease in Patients with
Diabetes: A Managed Care Perspective
Francois Laliberte, M.A., Groupe d'analyse, Ltee, Montreal, Quebec,
A retrospective analysis of medical claims and laboratory data from a
large managed care database was conducted to quantify the incremental
direct healthcare costs of CKD in patients with diabetes. Analyses
compared diabetes patients who developed CKD versus those who did not
for yearly direct healthcare costs, which consisted of outpatient
services, inpatient services and pharmacy dispensing claims. A total
of 30,480 patients with diabetes were identified, of whom 859 developed
CKD during the study period.
-- Abstract: The Effect of Anemia in Hypertensive Patients with Chronic
Kidney Disease: Hospital Costs and Length of Stay
Sandra Sulsky, M.P.H., Ph.D., ENVIRON International Corporation,
A retrospective analysis of hospital discharge records from the 2004
Nationwide Inpatient Sample of the Hospital Cost and Utilization
Project, which comprises approximately 90 percent of all hospital
discharges in the U.S., was conducted to determine the effect of anemia
on hospital costs and length of stay in hypertensive patients with CKD.
Analyses were adjusted for age, gender, income level, severity of
disease, and hospital characteristics to control for the confounding
effects of anemia, CK
|SOURCE Ortho Biotech Products, L.P.|
Copyright©2008 PR Newswire.
All rights reserved